KPI data tables

Sanofi operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

Sanofi Beyfortus Net Sales (Quarterly) (eur_millions)
PeriodBeyfortus sales
Q3 2026631
Q2 2026108
Q1 2026284
Q4 2025686
Q3 2025739
Q2 202572
Q1 2025284
Q4 2024841
Q3 2024645
Q2 202418
Q1 2024182
Q4 2023410
Q3 2023137

Source: Sanofi Form 6-K Exhibit 99.1 earnings releases, Beyfortus (RSV) row in the Vaccines net sales table and Appendix 1 (amounts in € million, quarterly flow not H1/9M/FY). Later filing wins. Q3 2026 €631 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm Q2 2026 €108 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm Q1 2026 €284 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000004/pressreleaseq12026english.htm Q4 2025 €686 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm Q3 2025 €739 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000026/pressreleaseq32025english.htm Q2 2025 €72 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm Q1 2025 €284 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm Q4 2024 €841 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000002/pressreleaseq42024english.htm Q3 2024 €645 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000020/pressreleaseq32024english.htm Q2 2024 €18 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000018/pressreleaseq22024english.htm Q1 2024 €182 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000011/pressreleaseq12024english.htm Q4 2023 €410 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000003/pressreleaseq42023english.htm Q3 2023 €137 million https://www.sec.gov/Archives/edgar/data/1121404/000112140423000026/pressreleaseq32023english.htm

Sanofi Dupixent Net Sales by Region (Quarterly) (eur_millions)
PeriodUnited StatesEuropeRest of World
Q3 20264,376588723
Q2 20263,899583672
Q1 20263,023563584
Q4 20253,182509555
Q3 20253,073504579
Q2 20252,807485540
Q1 20252,476459545

Source: Sanofi Form 6-K Exhibit 99.1 earnings releases, Dupixent row in net sales by medicine and geography (amounts in € million). Q3 2026 (30 Oct 2026) https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm Q2 2026 (30 Jul 2026) https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm Q1 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000004/pressreleaseq12026english.htm Q4 2025 / FY 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm Q3 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000026/pressreleaseq32025english.htm Q2 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm Q1 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm

Sanofi Net Sales by Region (Quarterly) (eur_millions)
PeriodUnited StatesEuropeRest of World
Q3 20268,6032,5793,262
Q2 20266,3442,1413,112
Q1 20265,2892,1633,057
Q4 20255,8032,4363,064
Q3 20256,8382,5893,007
Q2 20254,8782,1013,015
Q1 20254,6572,0433,195

Source: Sanofi Form 6-K Exhibit 99.1 earnings releases, Sales by geography table (amounts in € million). Q3 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm US 8,603 / Europe 2,579 / Rest of World 3,262. Q2 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm US 6,344 / Europe 2,141 / Rest of World 3,112. Q1 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000004/pressreleaseq12026english.htm 5,289 / 2,163 / 3,057. Q4 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm 5,803 / 2,436 / 3,064. Q3 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000026/pressreleaseq32025english.htm 6,838 / 2,589 / 3,007. Q2 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm 4,878 / 2,101 / 3,015. Q1 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm 4,657 / 2,043 / 3,195.

Sanofi Pharma Launches Net Sales (Quarterly) (eur_millions)
PeriodPharma launches
Q3 20261,390
Q2 20261,305
Q1 20261,171
Q4 20251,121
Q3 20251,046
Q2 2025897
Q1 2025847
Q4 2024827
Q3 2024727
Q2 2024689
Q1 2024606

Source: Sanofi Form 6-K Exhibit 99.1 earnings releases, Pharma launches (*) row in Appendix 1 net sales by medicine/vaccine (amounts in € million, quarterly flow not H1/9M/FY). Not the combined Launches (*, **) row. Later filing wins. Q3 2026 €1390 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm Q2 2026 €1305 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm Q1 2026 €1171 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000004/pressreleaseq12026english.htm Q4 2025 €1121 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm Q3 2025 €1046 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000026/pressreleaseq32025english.htm Q2 2025 €897 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm Q1 2025 €847 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm Q4 2024 €827 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000002/pressreleaseq42024english.htm Q3 2024 €727 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000020/pressreleaseq32024english.htm Q2 2024 €689 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000018/pressreleaseq22024english.htm Q1 2024 €606 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000011/pressreleaseq12024english.htm

Sanofi Vaccines Net Sales by Franchise (Quarterly) (eur_millions)
PeriodPolio/pertussis/Hib (incl. Heplisav-B from Q1 2026)Meningitis, travel, and endemicBeyfortusInfluenza, COVID-19
Q3 20268234766311,256
Q2 202670028710854
Q1 202666427828467
Q4 2025551227686575
Q3 20256424517391,525
Q2 202569330772141
Q1 202566830228473

Source: Sanofi Form 6-K Exhibit 99.1 earnings releases, Vaccines net sales table (amounts in € million). Q3 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm PPH 823 / meningitis, travel and endemic 476 / Beyfortus 631 / influenza, COVID-19 1256. Q2 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm PPH 700 / meningitis, travel and endemic 287 / Beyfortus 108 / influenza, COVID-19 54. Q1 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000004/pressreleaseq12026english.htm 664 / 278 / 284 / 67. Q4 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm 551 / 227 / 686 / 575. Q3 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000026/pressreleaseq32025english.htm 642 / 451 / 739 / 1525. Q2 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm 693 / 307 / 72 / 141. Q1 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm 668 / 302 / 284 / 73.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Sanofi (SNY) - KPIs | Sterling